Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles from Miscellaneous institutions in Madrid
Based on 71 articles published since 2008
||||

These are the 71 published articles about Osteoporosis that originated from Miscellaneous institutions in Madrid during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3
1 Guideline Recommendations on the effect of antidiabetic drugs in bone. 2017

Rozas-Moreno, Pedro / Reyes-García, Rebeca / Jódar-Gimeno, Esteban / Varsavsky, Mariela / Luque-Fernández, Inés / Cortés-Berdonces, María / Muñoz-Torres, Manuel / Anonymous800976. ·Sección de Endocrinología, Hospital General Universitario de Ciudad Real, Ciudad Real, España. Electronic address: pedrorozasm@yahoo.es. · Unidad de Endocrinología y Nutrición, Complejo Hospitalario Torrecárdenas; Servicio de Endocrinología, Clínica San Pedro, Almería, España. · Departamento de Endocrinología y Nutrición, Hospitales Universitarios Quirón Salud (Madrid Pozuelo, San Camilo, San José), Madrid, España. · Servicio de Endocrinología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. · Servicio de Endocrinología y Nutrición, Hospital Virgen de la Salud, Toledo, España. · Servicio de Endocrinología y Nutrición, Hospital Ruber Juan Bravo, Madrid, España. · UGC Endocrinología y Nutrición. Complejo Hospitalario Universitario de Granada. Departamento de Medicina. Universidad de Granada. Instituto de Investigación Biosanitaria de Granada, Granada, España. ·Endocrinol Diabetes Nutr · Pubmed #28440761.

ABSTRACT: OBJECTIVE: To provide recommendations on the effect of antidiabetic drugs on bone fragility to help select the most adequate antidiabetic treatment, especially in diabetic patients with high risk of fracture. PARTICIPANTS: Members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology. METHODS: The GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) was used to establish both the strength of recommendations and the quality of evidence. A systematic search was made in MEDLINE (Pubmed) using the following terms associated to the name of each antidiabetic drug: AND "osteoporosis", "fractures", "bone mineral density", "bone markers", "calciotropic hormones". Papers in English with publication date before 30 April 2016 were reviewed. Recommendations were jointly discussed by the Working Group. CONCLUSIONS: The document summaries the data on the potential effects of antidiabetic drugs on bone metabolism and fracture risk.

2 Guideline [SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update]. 2015

Etxebarria-Foronda, I / Caeiro-Rey, J R / Larrainzar-Garijo, R / Vaquero-Cervino, E / Roca-Ruiz, L / Mesa-Ramos, M / Merino Pérez, J / Carpintero-Benitez, P / Fernández Cebrián, A / Gil-Garay, E. ·Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España. Electronic address: ietxe@yahoo.es. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complexo Hospitalario Universitario Santiago Compostela, Santiago de Compostela, A Coruña, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario Infanta Leonor, Madrid, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complexo Hospitalario Pontevedra, Pontevedra, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario Virgen Macarena, Sevilla, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Unidad de Gestión Clínica del Aparato Locomotor, Área Sanitaria Norte de Córdoba, Pozoblanco, Córdoba, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Cátedra de Cirugía Ortopédica y Traumatología, Facultad de Medicina, Córdoba, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complejo Hospitalario de Ourense, Ourense, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz, Madrid, España. ·Rev Esp Cir Ortop Traumatol · Pubmed #26233814.

ABSTRACT: -- No abstract --

3 Guideline [Update of recommendations for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology]. 2015

Reyes-García, Rebeca / García-Martín, Antonia / Varsavsky, Mariela / Rozas-Moreno, Pedro / Cortés-Berdonces, María / Luque-Fernández, Inés / Gómez Sáez, José Manuel / Vidal Casariego, Alfonso / Romero Muñoz, Manuel / Guadalix Iglesias, Sonsoles / Fernández García, Diego / Jódar Gimeno, Esteban / Muñoz Torres, Manuel / Anonymous3690824. ·Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España; Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. Electronic address: rebecarg@yahoo.com. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España; Unidad de Endocrinología, Hospital Comarcal del Noroeste, Caravaca de la Cruz, Murcia, España. · Servicio de Endocrinología, Hospital de Sant Pau i Santa Tecla, Tarragona, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España; Servicio de Endocrinología, Hospital General de Ciudad Real, Ciudad Real, España. · Unidad de Endocrinología, Centro de Endocrinología, Diabetes y Nutrición, Madrid, España. · Servicio de Endocrinología, Hospital Virgen de la Salud de Toledo, Toledo, España. · Servicio de Endocrinología, Hospital Universitario de Bellvitge, Barcelona, España. · Sección de Endocrinología, Complejo Asistencial Universitario de León, León, España. · Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España. · Servicio de Endocrinología, Hospital Doce de Octubre, Madrid, España. · Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, España. · Servicio de Endocrinología, Hospital Universitario Quiron, Madrid, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. ·Endocrinol Nutr · Pubmed #25797189.

ABSTRACT: OBJECTIVE: To update previous recommendations developed by the Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology and Nutrition for the evaluation and treatment of osteoporosis associated to different endocrine and nutritional diseases. PARTICIPANTS: Members of the Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology and Nutrition. METHODS: Recommendations were formulated according to the GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in MEDLINE (Pubmed) using the following terms associated to the name of each condition: AND "osteoporosis", "fractures", "bone mineral density", and "treatment". Papers in English with publication date between 18 October 2011 and 30 October 2014 were included. The recommendations were discussed and approved by all members of the Working Group. CONCLUSIONS: This update summarizes the new data regarding evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions.

4 Guideline EMAS position statement: The ten point guide to the integral management of menopausal health. 2015

Neves-E-Castro, Manuel / Birkhauser, Martin / Samsioe, Goran / Lambrinoudaki, Irene / Palacios, Santiago / Borrego, Rafael Sanchez / Llaneza, Placido / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret. ·Clinica da Menopausa, Av. Luis Bivar, 93c-1 Dt, Lisboa 1050-143, Portugal. · Gynaecological Endocrinology and Reproductive Medicine, University of Berne, Gartenstrasse 67, CH-4052 Basel, Switzerland. · Department of Clinical Sciences, SUS University Hospital Lund, Lund University, SE-221 85 Lund, Sweden. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · Instituto Palacios, Salud y Medicina de la Mujer, C/Antonio Acuña, 9, 28009 Madrid, Spain. · DIATROS, Clínica de Atención a la Mujer, Barcelona, Spain. · Department of Obstetrics and Gynecology, University Central Hospital of Asturias, University of Oviedo, 33011 Oviedo, Spain. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No: 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit, Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:05, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. Electronic address: margaret.rees@st-hildas.ox.ac.uk. ·Maturitas · Pubmed #25757366.

ABSTRACT: With increased longevity and more women becoming centenarians, management of the menopause and postreproductive health is of growing importance as it has the potential to help promote health over several decades. Women have individual needs and the approach needs to be personalised. The position statement provides a short integral guide for all those involved in menopausal health. It covers diagnosis, screening for diseases in later life, treatment and follow-up.

5 Guideline [Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients]. 2014

Martínez, Esteban / Jódar Gimeno, Esteban / Reyes García, Rebeca / Carpintero, Pedro / Casado, José Luis / Del Pino Montes, Javier / Domingo Pedrol, Pere / Estrada, Vicente / Maalouf, Jorge / Negredo, Eugenia / Ocampo, Antonio / Muñoz-Torres, Manuel / Anonymous4920778 / Anonymous4930778 / Anonymous4940778 / Anonymous4950778. ·Unidad de Enfermedades Infecciosas, Hospital Clínic, Barcelona, España. · Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, España. · Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España. Electronic address: rebecarg@yahoo.com. · Servicio de Traumatología, Hospital Universitario Reina Sofía, Córdoba, España. · Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. · Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, España. · Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Medicina Interna/Enfermedades Infecciosas, Hospital Clínico San Carlos, Madrid, España. · Unidad de Metabolismo Mineral, Departamento de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Servicio de Medicina Interna, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, España. · Unidad VIH, Hospital Xeral-Cies, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Pontevedra, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. ·Enferm Infecc Microbiol Clin · Pubmed #24332711.

ABSTRACT: OBJECTIVE: To provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients. PARTICIPANTS: Members of scientific societies related to bone metabolism and HIV: Grupo de Estudio de Sida (GeSIDA), Sociedad Española de Endocrinología y Nutrición (SEEN), Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM), and Sociedad Española de Fractura Osteoporótica (SEFRAOS). METHODS: A systematic search was carried out in PubMed, and papers in English and Spanish with a publication date before 28 May 2013 were included. Recommendations were formulated according to GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) setting both their strength and the quality of supporting evidence. Working groups were established for each major part, and the final resulting document was later discussed in a face-to-face meeting. All the authors reviewed the final written document and agreed with its content. CONCLUSIONS: The document provides evidence-based practical recommendations on the detection and treatment of bone disease in HIV-infected patients.

6 Guideline [Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up]. 2013

Martínez Díaz-Guerra, Guillermo / Jódar Gimeno, Esteban / Reyes García, Rebeca / Gómez Sáez, José Manuel / Muñoz-Torres, Manuel / Anonymous200758. ·Servicio de Endocrinología, Hospital Doce de Octubre, Madrid, España. ·Endocrinol Nutr · Pubmed #23660008.

ABSTRACT: OBJECTIVE: To provide practical recommendations for evaluation and follow-up of patients with normocalcemic primary hyperparathyroidism. PARTICIPANTS: Members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology. METHODS: A systematic search was made in MEDLINE (PubMed), using the terms normocalcemic primary hyperparathyroidism and primary hyperparathyroidism, for articles in English published before 22 November 2012. Literature was reviewed by 2 members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology, and after development of recommendations, the manuscript was reviewed by all other members of the Group, and their suggestions were incorporated. CONCLUSIONS: The document provides practical recommendations for evaluation and follow-up of patients with normocalcemic primary hyperparathyroidism. There is however little evidence available about different aspects of this disease, mainly progression rate and clinical impact. More data are therefore needed before definite recommendations may be made.

7 Editorial [Osteoporosis: How, when and how far]. 2016

López García-Franco, Alberto. ·Medicina Familiar y Comunitaria, Centro de Salud Dr. Mendiguchía Carriche, Leganés, Madrid, España; Presidente de la Sociedad Madrileña de Medicina Familiar y Comunitaria (SoMaMFyC), Madrid, España; Coordinador del grupo de la mujer del PAPPS, España. Electronic address: alopezgfp@gmail.com. ·Aten Primaria · Pubmed #27049040.

ABSTRACT: -- No abstract --

8 Editorial Association between vitamin D and falls in young postmenopausal women. 2016

Palacios, Santiago. ·Palacios Institute of Women's Health, Madrid, Spain. ·Menopause · Pubmed #26818014.

ABSTRACT: -- No abstract --

9 Editorial Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. 2015

Palacios, S / Mejía, A. ·Palacios Institute of Women's Health , Madrid , Spain. ·Climacteric · Pubmed #25740608.

ABSTRACT: Osteoporosis is a chronic disease which may require treatment for many years and requires not only individual management but often sequential or combination treatments. Monotherapy with antiresorptives is usually the first choice. Sometimes, it is necessary to modify this option for therapeutic failure or for the time of use and risk of side-effects. Due to their different mode of action, therapy with anabolic drugs has increased our options in the treatment of osteoporosis. Postmenopausal women and men with severe and progressive osteoporosis despite antiresorptive treatment ('therapeutic failure') should be evaluated for treatment with an anabolic option. Moreover, anabolic agents are indicated for 18-24 months in patients at high risk. Then, sequential antiresorptive therapy is recommended to maintain drug increases in bone mass and support secondary mineralization of the newly formed bone. Combination therapies of antiresorptives and anabolic agents have shown a significant increase in bone mineral density compared to monotherapies. However, none of the combinations have been studied for the prevention of fractures. Combination therapy may not be recommended because of the possible increase in cost.

10 Review Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. 2018

Ramírez, Julio / Nieto-González, Juan Carlos / Curbelo Rodríguez, Rafael / Castañeda, Santos / Carmona, Loreto. ·Rheumatology Department, Arthritis Unit, Hospital Clinic and IDIBAPS, Barcelona, Spain. Electronic address: julramga@gmail.com. · Rheumatology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. · Instituto de Salud Musculoesquelética, Madrid, Spain. · Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain. ·Semin Arthritis Rheum · Pubmed #29290311.

ABSTRACT: OBJECTIVES: To describe the prevalence of osteoporosis, the prevalence and incidence of fractures, and the frequency of risk factors for low bone mineral density (BMD) in axial spondyloarthritis (Ax-SpA). METHODS: A systematic review and meta-analysis of observational studies was conducted. Medline, Embase, and Cochrane Library databases were searched with a sensitive strategy. Large cross-sectional and longitudinal studies published in the last 10 years (January 2006-2016) with representative samples of patients with Ax-SpA estimating the frequency of osteoporosis, risk factors or fractures were selected. RESULTS: After screening 3597 titles and abstracts, 46 studies were reviewed in detail, of which 35 studies had a cross-sectional design, 5 were prospective and 6 retrospective; 21 studies compared Ax-SpA patients with a control group-either healthy individuals (18 studies) or subjects with other diseases (6 studies). The prevalence of osteoporosis varied from 11.7% to 34.4% and that of fractures from 11% to 24.6%. Alcohol intake (58-61%), use of corticosteroids (11.7-66.9%), and 25-OH vitamin D deficiency (26-76%) were unexpectedly high in Ax-SpA patients. CONCLUSION: The prevalence of osteoporosis and fractures in Ax-SpA varies between 11.7% and 34.4% and 11-24.6%, respectively. Alcohol intake, steroid use, and low levels of 25-OH-vitamin D should be taken into account in osteoporosis assessment in patients with Ax-SpA. Inconsistent results, lack of bone quality assessment, and high likelihood of bias of the published studies confirm the need for performing well-designed studies.

11 Review New options for menopausal symptoms after 15 years of WHI Study. 2017

Palacios, Santiago / Coronado, Pluvio J. ·Director of Instituto Palacios, Madrid, Spain - ipalacios@institutopalacios.com. · Department of Obstetrics and Gynecology, San Carlos Clinic Hospital, Madrid, Spain. ·Minerva Ginecol · Pubmed #27973466.

ABSTRACT: Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene). In addition to lifestyle changes, treatments for the risk of fragility fracture include calcium and vitamin D, hormone treatment, selective estrogen receptor modulators (raloxifene, BZA), bisphosphonates, strontium ranelate, denosumab, and teriparatide. This article reviews treatment options and provides treatment algorithms for women with menopausal symptoms.

12 Review Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. 2016

Baillet, Athan / Gossec, Laure / Carmona, Loreto / Wit, Maarten de / van Eijk-Hustings, Yvonne / Bertheussen, Heidi / Alison, Kent / Toft, Mette / Kouloumas, Marios / Ferreira, Ricardo J O / Oliver, Susan / Rubbert-Roth, Andrea / van Assen, Sander / Dixon, William G / Finckh, Axel / Zink, Angela / Kremer, Joel / Kvien, Tore K / Nurmohamed, Michael / van der Heijde, Desirée / Dougados, Maxime. ·Department of Rheumatology, Université Joseph Fourier, GREPI-CNRS, Grenoble Hospital, France. · Department of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France. · Instituto de Salud Musculoesquelética, Madrid, Spain. · EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland. · Integrated Care, Maastricht University Medical Centre, Maastricht, The Netherlands. · Salisbury NHS Foundation Trust Hospital, Salisbury, UK. · Cyprus League Against Rheumatism, Cyprus, Nikosia, Cyprus. · Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra; Health Sciences Research Unit: Nursing (UICiSA:E), Coimbra, Portugal. · Independent Nurse Consultant, North Devon, UK. · Department of Internal Medicine, University of Cologne, Cologne, Germany. · Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. · Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. · Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland. · Epidemiology Unit, German Rheumatism Research Centre, and Rheumatology, Charité, University Medicine, Berlin, Germany. · Albany Medical College and The Center for Rheumatology, Albany, USA. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · Amsterdam Rheumatology immunology Center | VUmc and Reade, The Netherlands. · Department of Rheumatology, Leiden University Medical Center, The Netherlands. · Department of Rheumatology, Paris Descartes University-Hôpital Cochin. Assistance Publique-Hôpitaux de Paris. INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France. ·Ann Rheum Dis · Pubmed #26984008.

ABSTRACT: In chronic inflammatory rheumatic diseases, comorbidities such as cardiovascular diseases and infections are suboptimally prevented, screened for and managed. The objective of this European League Against Rheumatism (EULAR) initiative was to propose points to consider to collect comorbidities in patients with chronic inflammatory rheumatic diseases. We also aimed to develop a pragmatic reporting form to foster the implementation of the points to consider. In accordance with the EULAR Standardised Operating Procedures, the process comprised (1) a systematic literature review of existing recommendations on reporting, screening for or preventing six selected comorbidities: ischaemic cardiovascular diseases, malignancies, infections, gastrointestinal diseases, osteoporosis and depression and (2) a consensus process involving 21 experts (ie, rheumatologists, patients, health professionals). Recommendations on how to treat the comorbidities were not included in the document as they vary across countries. The literature review retrieved 42 articles, most of which were recommendations for reporting or screening for comorbidities in the general population. The consensus process led to three overarching principles and 15 points to consider, related to the six comorbidities, with three sections: (1) reporting (ie, occurrence of the comorbidity and current treatments); (2) screening for disease (eg, mammography) or for risk factors (eg, smoking) and (3) prevention (eg, vaccination). A reporting form (93 questions) corresponding to a practical application of the points to consider was developed. Using an evidence-based approach followed by expert consensus, this EULAR initiative aims to improve the reporting and prevention of comorbidities in chronic inflammatory rheumatic diseases. Next steps include dissemination and implementation.

13 Review [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates]. 2016

Moro Álvarez, María Jesús / Neyro, José Luis / Castañeda, Santos. ·Servicio de Medicina Interna, Hospital Universitario Infanta Leonor, Madrid, España. Electronic address: mariajesus.moro@salud.madrid.org. · Servicio de Ginecología y Obstetricia, Hospital Universitario Cruces, Baracaldo, Vizcaya, España. · Servicio de Reumatología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, España. ·Med Clin (Barc) · Pubmed #26048545.

ABSTRACT: Oral bisphosphonates (BF) are drugs widely used in the treatment of osteoporosis and placed as first-line treatment for osteoporosis in most clinical guidelines. BF are effective drugs that reduce the incidence of fractures and even reduce mortality. Because of their great affinity for bone, BF have shown that even when they are discontinued still offer a latent protective effect on bone mineral density, maintaining their anti-fracture effect. However, prolonged use for years has been linked to the gradual emergence of complications such as osteonecrosis of the jaw or atypical femur fractures, which have raised questions as when to hold and when to make a final or temporary break, recognized as periods of rest or "therapeutic holidays" of these drugs. Thus, in patients treated with BF for a period of 3-5 years with a low risk of fracture, the drug should be discontinued and restarted when there is an indication for treatment. In contrast, in patients with moderate risk, therapeutic holidays are advised, while reassessing after 2-3 years for restarting purposes. Finally, in patients with high risk of fracture, treatment with BF should not be withdrawn.

14 Review The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. 2015

Marques, Andréa / Ferreira, Ricardo J O / Santos, Eduardo / Loza, Estíbaliz / Carmona, Loreto / da Silva, José António Pereira. ·Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal Health Sciences Research Unit: Nursing (UICiSA:E), Coimbra, Portugal. · Instituto de Salud Musculoesquelética-InMusc, Madrid, Spain. · Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal Faculty of Medicine, Clínica Universitária de Reumatologia, University of Coimbra, Coimbra, Portugal. ·Ann Rheum Dis · Pubmed #26248637.

ABSTRACT: OBJECTIVES: To identify and synthesise the best available evidence on the accuracy of the currently available tools for predicting fracture risk. METHODS: We systematically searched PubMed MEDLINE, Embase and Cochrane databases to 2014. Two reviewers independently selected articles, collected data from studies, and carried out a hand search of the references of the included studies. The Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS) checklist was used, and the primary outcome was the area under the curve (AUC) and 95% CIs, obtained from receiver operating characteristic (ROC) analyses. We excluded tools if they had not been externally validated or were designed for specific disease populations. Random effects meta-analyses were performed with the selected tools. RESULTS: Forty-five studies met inclusion criteria, corresponding to 13 different tools. Only three tools had been tested more than once in a population-based setting: FRAX (26 studies in 9 countries), GARVAN (6 studies in 3 countries) and QFracture (3 studies in the UK, 1 also including Irish participants). Twenty studies with these three tools were included in a total of 17 meta-analyses (for hip or major osteoporotic fractures; men or women; with or without bone mineral density). CONCLUSIONS: Most of the 13 tools are feasible in clinical practice. FRAX has the largest number of externally validated and independent studies. The overall accuracy of the different tools is satisfactory (>0.70), with QFracture reaching 0.89 (95% CI 0.88 to 0.89). Significant methodological limitations were observed in many studies, suggesting caution when comparing tools based solely on the AUC.

15 Review Vitamin D supplementation review and recommendations for women diagnosed with breast or ovary cancer in the context of bone health and cancer prognosis/risk. 2015

Martin-Herranz, Ana / Salinas-Hernández, Pedro. ·Department of Medical Oncology, Hospital La Zarzuela, Madrid, Spain. Electronic address: amartinherranz@hotmail.com. · Department of Medical Oncology, Hospital La Zarzuela, Madrid, Spain. ·Crit Rev Oncol Hematol · Pubmed #26068240.

ABSTRACT: Vitamin D review and supplementation recommendations for women diagnosed with breast or ovary cancer have been defined in the context of bone health and cancer prognosis/risk taking as reference wider cancer patients and postmenopausal women. This specific group has been selected due to its higher osteoporosis risk versus postmenopausal women. Early vitamin D supplementation could help maintain bone health, as well as potentially enhance cancer survival rate. Factors considered for supplementation include daily dose, periodicity, chemical form, administration, and serum levels. Sufficient vitamin D serum levels are recommended to be above 30 ng/ml (75 nmol/l). Maintenance oral supplementation equivalent to a minimum daily dosage of 800-1000 IU (20-25 μg) cholecalciferol provided in a daily to monthly bases is preferred, also advised to start with higher dosages when vitamin D serum levels are <10 ng/ml (25 nmol/l). Calcidiol supplementation is more effective, making it advantageous for cases with very low or difficult to raise vitamin D serum levels.

16 Review The position of strontium ranelate in today's management of osteoporosis. 2015

Reginster, J-Y / Brandi, M-L / Cannata-Andía, J / Cooper, C / Cortet, B / Feron, J-M / Genant, H / Palacios, S / Ringe, J D / Rizzoli, R. ·Department of Public Health, Epidemiology and Health Economics, University of Liège, 4020, Liège, Belgium. jyreginster@ulg.ac.be. · Metabolic Bone Unit, Department of Internal Medicine, University of Florence, Florence, Italy. · Servicio de Metabolismo Óseo y Mineral, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Asturias, Spain. · MRC Lifecourse Epidemiology Unit and NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK. · Service de Rhumatologie, Hôpital Roger Salengro, Lille, France. · Service de Chirurgie Orthopédique et Traumatologique, Hôpital Saint Antoine, UPMC, Paris, France. · Departments of Radiology, Medicine, Epidemiology and Orthopedic Surgery, University of California, San Francisco, CA, USA. · Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain. · Med Klinik 4, Klinikum Leverkusen, Akadem, Lehrkrankenhaus, University of Cologne, Cologne, Germany. · Division of Bone Diseases, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland. ·Osteoporos Int · Pubmed #25868510.

ABSTRACT: Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving, especially in patient with severe osteoporosis or patients who cannot take certain osteoporosis medications due to issues of contraindications or tolerability. Following recent regulatory changes, strontium ranelate is now indicated in patients with severe osteoporosis for whom treatment with other osteoporosis treatments is not possible, and without contraindications including uncontrolled hypertension, established, current or past history of ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. We review here today's evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy of strontium ranelate is maintained in patients with severe osteoporosis without contraindications and also demonstrated how the new target population mitigates risk. Strontium ranelate is therefore an important alternative in today's management of osteoporosis, with a positive benefit-risk balance, provided that the revised indication and contraindications are followed and cardiovascular risk is monitored. The bone community should be reassured that there remain viable alternatives in patients in whom treatment with other agents is not possible and protection against the debilitating effects of fracture is still feasible in patients with severe osteoporosis.

17 Review Chronic iron deficiency as an emerging risk factor for osteoporosis: a hypothesis. 2015

Toxqui, Laura / Vaquero, M Pilar. ·Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Novais 10, Madrid 28040, Spain. laura.toxqui@ictan.csic.es. · Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), C/José Antonio Novais 10, Madrid 28040, Spain. mpvaquero@ictan.csic.es. ·Nutrients · Pubmed #25849944.

ABSTRACT: Iron is essential in oxygen transport and participates in many enzymatic systems in the body, with important roles in collagen synthesis and vitamin D metabolism. The relationship between iron and bone health comes from clinical observations in iron overload patients who suffered bone loss. The opposite scenario--whether iron deficiency, with or without anemia, affects bone metabolism--has not been fully addressed. This is of great interest, as this nutrient deficiency is a worldwide public health problem and at the same time osteoporosis and bone alterations are highly prevalent. This review presents current knowledge on nutritional iron deficiency and bone remodeling, the biomarkers to evaluate iron status and bone formation and resorption, and the link between iron and bone metabolism. Finally, it is hypothesized that chronic iron deficiency induces bone resorption and risk of osteoporosis, thus complete recovery from anemia and its prevention should be promoted in order to improve quality of life including bone health. Several mechanisms are suggested; hence, further investigation on the possible impact of chronic iron deficiency on the development of osteoporosis is needed.

18 Review Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women. 2015

Palacios, S / Mejía Ríos, A. ·Palacios Institute of Women's Health, Madrid, Spain. ipalacios@institutopalacios.com. · Palacios Institute of Women's Health, Madrid, Spain. ·Drugs Today (Barc) · Pubmed #25756066.

ABSTRACT: The decrease of estrogen in postmenopausal women has been associated with the presence of different symptoms such as vasomotor symptoms, vulvovaginal atrophy, bone loss, sleep disturbances, and mood and sexual activity alterations. Hormone replacement therapy with estrogen and progestins has been used to improve menopausal symptoms; however, there are still concerns regarding its safety and tolerability, as some progestins have been shown to increase breast cancer and cardiovascular risk. Bazedoxifene is a third-generation selective estrogen receptor modulator (SERM) used for osteoporosis management in postmenopausal women at fracture risk that has demonstrated a powerful antiestrogenic effect on the endometrium. Today we have a new alternative called the tissue-selective estrogen complex (TSEC), which combines bazedoxifene and conjugated estrogens and is designed not only to improve menopausal symptoms and vulvovaginal atrophy but also to prevent bone loss. Therefore, it maintains the benefits of estrogen therapy while antagonizing the stimulation effects on the endometrium and mammary gland without the effects associated with progestins.

19 Review Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. 2015

Loza, Estíbaliz / Lajas, Cristina / Andreu, Jose Luis / Balsa, Alejandro / González-Álvaro, Isidoro / Illera, Oscar / Jover, Juan Ángel / Mateo, Isabel / Orte, Javier / Rivera, Javier / Rodríguez Heredia, José Manuel / Romero, Fredeswinda / Martínez-López, Juan Antonio / Ortiz, Ana María / Toledano, Esther / Villaverde, Virginia / Carmona, Loreto / Castañeda, Santos. ·Madrilenian Society of Rheumatology, Madrid, Spain. ·Rheumatol Int · Pubmed #25543267.

ABSTRACT: The objective of the study was to develop evidence-based and practical recommendations for the detection and management of comorbidity in patients with rheumatoid arthritis (RA) in daily practice. We used a modified RAND/UCLA methodology and systematic review (SR). The process map and specific recommendations, based on the SR, were established in discussion groups. A two round Delphi survey permitted (1) to prioritize the recommendations, (2) to refine them, and (3) to evaluate their agreement by a large group of users. The recommendations cover: (1) which comorbidities should be investigated in clinical practice at the first and following visits (including treatments, risk factors and patient's features that might interfere with RA management); (2) how and when should comorbidities and risk factors be investigated; (3) how to manage specific comorbidities, related or non-related to RA, including major adverse events of RA treatment, and to promote health (general and musculoskeletal health); and (4) specific recommendations to assure an integral care approach for RA patients with any comorbidity, such as health care models for chronic inflammatory patients, early arthritis units, relationships with primary care, specialized nursing care, and self-management. These recommendations are intended to guide rheumatologists, patients, and other stakeholders, on the early diagnosis and management of comorbidity in RA, in order to improve disease outcomes.

20 Review Bone health in patients with prostate cancer. 2014

Miñana, B / Cózar, J M / Alcaraz, A / Morote, J / Gómez-Veiga, F J / Solsona, E / Rodríguez-Antolín, A / Carballido, J. ·Servicio de Urología, Hospital Morales Meseguer, Universidad Católica San Antonio, UCAM, Murcia, España. Electronic address: bernardino.minana@gmail.com. · Servicio de Urología, Hospital Virgen de las Nieves, Granada, España. · Servicio de Urología, Hospital Clínic, Barcelona, España. · Servicio de Urología, Hospital Vall de Hebrón, Barcelona, España. · Servicio de Urología, CHUAC, A Coruña, España. · Servicio de Urología, IVO, Valencia, España. · Servicio de Urología, Hospital Doce de Octubre, Madrid, España. · Servicio de Urología, Hospital Puerta de Hierro, Madrid, España. ·Actas Urol Esp · Pubmed #24934457.

ABSTRACT: CONTEXT: In patients with prostate cancer, bone health is compromised by advanced age at diagnosis, androgen suppression treatments and the developmentofbone metastases. In this paper the medical literature is reviewed in order to update the state of the art on their incidence, prevention and management. EVIDENCE ACQUISITION: A literature review about bone involvement in patients with prostate cancer in different clinical settings is performed. SYNTHESIS OF THE EVIDENCE: Decreased bone mineral density is higher in patients diagnosed of prostate cancer before starting treatment than in healthy men with the same age. During the first year of treatment, a severe loss bone density is reported due to androgen suppression therapy. From then on, loss bone density seems to slow down, persisting at long-term. It is important to know the starting point and the dynamics of loss bone in order to prevent its progression. The skeletal events have an important impact on quality of life in patients with prostate cancer. Both Denosumab and Zoledronic Acid have proven effective in reducing loss bone. CONCLUSIONS: The prevention and management of bone involvement in patients with prostate cancer is critical to quality of life in these patients and requires an individualized approach. Before starting a prolonged androgen deprivation, baseline risk of fracture should be evaluated in order to adopt the proper protective measures. In patients with metastases, early treatments reducing the risk of bone events should be taken into account.

21 Review The relevance of biomaterials to the prevention and treatment of osteoporosis. 2014

Arcos, D / Boccaccini, A R / Bohner, M / Díez-Pérez, A / Epple, M / Gómez-Barrena, E / Herrera, A / Planell, J A / Rodríguez-Mañas, L / Vallet-Regí, M. ·Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain; Dpto. Química Inorgánica y Bioinorgánica, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital, 12 de Octubre i+12, Madrid, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; University of Erlangen-Nuremberg, Institute of Biomaterials, 91058 Erlangen, Germany. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; RMS Fundation, CH-2544 Bettlach, Switzerland. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; Hospital del Mar-IMIM, Department Internal Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; University of Duisburg-Essen, Inorganic Chemistry and Center for Nanointegration Duisburg-Essen (CeNIDE), D-45117 Essen, Germany. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; Servicio Cirugia Ortopedica & Traumatologia, Hospital La Paz, IdiPAZ, Universidad Autonoma Madrid, Madrid 28046, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; University of Zaragoza, Department of Surgery, E-50009 Zaragoza, Spain; Miguel Servet University Hospital, Department of Orthopaedic Surgery & Traumatology, Zaragoza 50009, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain; Institute of Bioengineering of Catalonia IBEC, BaldiriReixac 15-20, Barcelona 08028, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; University Hospital Getafe, Division Geriatric Medicine, Madrid, Spain. · Envejecimiento: red de excelencia española y europea para la prevención y tratamiento local de fracturas osteoporóticas, MINECO, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain; Dpto. Química Inorgánica y Bioinorgánica, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital, 12 de Octubre i+12, Madrid, Spain. Electronic address: vallet@farm.ucm.es. ·Acta Biomater · Pubmed #24418434.

ABSTRACT: Osteoporosis is a worldwide disease with a very high prevalence in humans older than 50. The main clinical consequences are bone fractures, which often lead to patient disability or even death. A number of commercial biomaterials are currently used to treat osteoporotic bone fractures, but most of these have not been specifically designed for that purpose. Many drug- or cell-loaded biomaterials have been proposed in research laboratories, but very few have received approval for commercial use. In order to analyze this scenario and propose alternatives to overcome it, the Spanish and European Network of Excellence for the Prevention and Treatment of Osteoporotic Fractures, "Ageing", was created. This network integrates three communities, e.g. clinicians, materials scientists and industrial advisors, tackling the same problem from three different points of view. Keeping in mind the premise "living longer, living better", this commentary is the result of the thoughts, proposals and conclusions obtained after one year working in the framework of this network.

22 Review [Variability in the recommendations for the clinical management of osteoporosis]. 2014

Sanfélix-Genovés, José / Catalá-López, Ferrán / Sanfélix-Gimeno, Gabriel / Hurtado, Isabel / Baixauli, Cristóbal / Peiró, Salvador. ·Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España; Fundación de Investigación del Hospital Clínico Universitario-Instituto de Investigación Sanitaria (INCLIVA), Valencia, España. Electronic address: sanfelix_jos@gva.es. · Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España; División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España. · Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España. ·Med Clin (Barc) · Pubmed #23332628.

ABSTRACT: BACKGROUND AND OBJECTIVE: Analysis of the variability in the recommendations of the main guidelines and clinical documents for the management of osteoporosis. MATERIAL AND METHOD: Searches were carried out in PubMed, Google, web pages of national and international scientific societies related to the management of osteoporosis, and agencies that develop guidelines. We analyzed guidelines and clinical documents that included recommendations for the indication of bone densitometry and/or pharmacological treatment, which could influence the management of osteoporosis in the Spanish National Health System, which have been published between 2006 and 2012. RESULTS: We included 12 documents. Eleven recommend performing bone densitometry upon assessing women risk factors, but the number and type of risk factors vary between documents: 6 recommend its implementation to all women over 65 years, 4 in men aged 65-70 years, and 3 when there is radiological suspicion of osteoporosis. There is agreement on the recommendations on the indication for densitometry to monitor drug response. In primary prevention, all national documents combined risk factors and densitometric osteoporosis and 3 of them recommend individual assessment according to risk factors. Most of the international guidelines require the calculation of risk with the FRAX(®) tool. In secondary prevention, all documents recommend treatment in cases of hip or clinical vertebral fracture; in men, and for the rest of fractures, the recommendations are heterogeneous. CONCLUSIONS: Overall there is a high variability in the recommendations of guidelines and other documents for the management of osteoporosis.

23 Review Identifying and managing patients at high risk for fractures: conclusions from the second Spanish multidisciplinary forum-parathyroid hormone use in osteoporotic patients at high risk for fractures. 2012

Jódar Gimeno, Esteban. ·Servicio de Endocrinología y Nutrición Clínica, Hospital Universitario Quirón, Madrid, Spain. ·Drugs R D · Pubmed #23193980.

ABSTRACT: PURPOSE: The Second Multidisciplinary Forum: Parathyroid Hormone (PTH) Use in Osteoporotic Patients at High Risk for Fractures (HRF) was conducted to identify specific findings that would be helpful for defining high-risk status and guiding the use of parathyroid hormone 1-84 (PTH1-84) as an anabolic therapy in daily clinical practice. This article summarizes the conclusions from the meeting. MATERIALS AND METHODS: Based on three typical case records, and the final conclusions from the first Forum (held in 2010), several questions were posed regarding daily clinical practice definitions of HRF and use of PTH1-84, through a series of 19 meetings throughout Spain. The main discussion topics and agreed conclusions were collected by meeting coordinators and shared at a meeting held in May 2011. After extensive discussions, which also included other organizational and educational matters, some newly agreed conclusions were reached. RESULTS: The consensus was that an HRF patient is usually thought of as being elderly (aged >70 years), with a very low bone mass or a prevalent fracture, and some other associated risk factors. High-risk groups who were identified included patients with neurologic diseases, institutionalized individuals, and patients receiving long-term steroid therapy. PTH1-84 was considered a safe and effective drug, having added value because of its analgesic effect and good level of patient adherence. Opportunities for improved PTH1-84 use were identified, such as better patient selection and follow-up based on localization and specialty. Some improvement opportunities were also detected in organizational and educational areas. CONCLUSION: The Forum identified differences between clinical recommendations and daily clinical practice. Some elements, involving both organizational and educational areas that could help to reduce such discrepancies, are described.

24 Review Dual energy X-ray absorptimetry: fundamentals, methodology, and clinical applications. 2012

Lorente Ramos, R M / Azpeitia Armán, J / Arévalo Galeano, N / Muñoz Hernández, A / García Gómez, J M / Gredilla Molinero, J. ·Unidad Central de Radiodiagnóstico de la CAM, Hospital Infanta Leonor, Madrid, España. rosa.lorenteramos@salud.madrid.org ·Radiologia · Pubmed #22285678.

ABSTRACT: Dual-energy X-ray absorptiometry (DXA; DEXA) is the technique of choice to diagnose osteoporosis and to monitor the response to treatment. It is also useful for measuring body composition. In recent years, new applications have been developed, including vertebral morphometry through the study of the lateral spine, prosthesis integration in orthopedics, and lipodystrophy in HIV+ patients, although its use in these cases is not well established. DXA densitometry is accurate and precise. It is essential to optimize each step of the diagnostic process, taking care to ensure the best acquisition, image analysis, and interpretation of the results. Thus, to obtain the greatest utility from DXA, radiologists need to know the technique, its indications, and its pitfalls. This article reviews the fundamentals, modalities, methods, and clinical applications of DXA.

25 Review EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. 2012

Palacios, Santiago / Brincat, Mark / Erel, C Tamer / Gambacciani, Marco / Lambrinoudaki, Irene / Moen, Mette H / Schenck-Gustafsson, Karin / Tremollieres, Florence / Vujovic, Svetlana / Rees, Margaret / Rozenberg, Serge. ·Palacios Institute of Woman's Health Antonio Acuna, Madrid, Spain. ipalacios@institutopalacios.com ·Maturitas · Pubmed #22176952.

ABSTRACT: Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.

Next